CDKN2A gene inactivation in epithelial sporadic ovarian cancer

British Journal of Cancer

Volumn 80, Issue 12, 1999, Pages 1920-1926

  Niederacher, D ^a,c   Yan, H Y ^a,b   An, H X ^a   Bender, H G ^a   Beckmann, M W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Third Hospital of Hebei Medical University   (China)

^c Molekulargenetisches Labor   (Germany)

Author keywords

9p21 22; CDKN2A gene; Immunohistochemistry; LOH; Ovarian cancer; RT PCR

Indexed keywords

ALPHA INTERFERON; CELL CYCLE PROTEIN; MESSENGER RNA; PROTEIN P16; REGULATOR PROTEIN;

ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CHROMOSOMAL LOCALIZATION; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EXON; FEMALE; GENE DELETION; GENE FUNCTION; GENE INACTIVATION; GENE LOCATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MARKER GENE; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOMA, PAPILLARY; DNA METHYLATION; DNA PRIMERS; FEMALE; GENE DELETION; GENES, P16; GENETIC MARKERS; HOMOZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0032772435     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690621     Document Type: Article

References (29)

1. An HX, Niederacher D, Beckmann MW, Göhring UJ, Scharl A, Picard F, van Roeyen C, Schnürch HG and Bender HG (1995) ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 74: 57-63
2. Beckmann MW, An H-X, Niederacher D, Köhrer K, Finken-Eigen M, Schröder W, Schnürch HG and Bender HG (1996a) Oncogene amplification in archival ovarian carcinoma detected by fluorescent differential polymerase chain reaction - a routine analytical approach. Int J Gynecol Cancer 6: 291-297
3. Beckmann MW, Picard F, An HX, van Roeyen CR, Dominik SI, Mosny DS, Schnürch HG, Bender HG and Niederacher D (1996b) Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast. Br J Cancer 73: 1220-1226
4. Beckmann MW, Niederacher D, Massenkeil G, Tutschek B, Beckmann A, Schenko G, Schnürch HG and Bender HG (1996c) Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology 53: 441-447
5. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blangrund JE and Sidransky D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-416
6. Campbell IG, Foulkes WD, Beynon G, Davis M and Englefield P (1995) LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer 63: 222-225
7. Chenevix-Trench G, Kerr J, Friedlander M, Hurst T, Sanderson B, Coglan M, Ward B, Leary J and Khoo SK (1994) Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in tumors. Am J Hum Gene 55: 143-149
8. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC and Jenkins RB (1993) Human epithelial ovarian cancer allelotype. Cancer Res 53: 2393-2398
9. Costello JF, Berger MS, Huang HS and Cavence WK (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410
10. Del Tito BJ Jr, Poff HE 3rd, Novotny MA, Cartledge DM, Walker RI II, Earl CD and Bailey AL (1998) Automated fluorescent analysis procedure for enzymatic mutation detection. Clin Chem 44: 731-739
11. Devlin J, Elder PA, Gabra H, Steel CM and Knowles MA (1996) High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer 73: 420-123
12. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, Hurst T, Khoo SK and Parsons PG (1997) Increased expression of cyclin-dependent Chinese inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer (Pred Oncol) 74: 57-63
13. Eiriksdottir G, Sigurdsson A, Jonasson JG, Agnarsson BA, Sigurdsson II, Gudmundsson J, Bergthorsson JT, Barkardottir RB, Egilsson V and Ingvarsson S (1995) Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer 64: 378-382
14. Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K and Murata Y (1997) Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 74: 148-1550
15. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCapiro JA and Keyomarsi K (1996) Cyclin E, a redudant cyclin in breast cancer. Proc Natl Acad Sci USA 93: 15215-15220
16. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM and Jones PA (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535
17. Hatta Y, Hirama T, Takeuchi S, Lee E, Pham E, Miller CW, Strohmeyer T, Wilczynski SP, Melmed S, Koeffler HP Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E and Day (1995) Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol 154, 1954-1957
18. RS 3rd, Johnson BE and Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
19. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD and Gazdar AF (1995) Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 87: 1224-1229
20. Lo KW, Cheung ST. Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC and Huang DP (1996) Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725
21. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D (1995) 5′ GpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in humun cancers. Natl Med 1: 686-692
22. Milde-Langosch K, Ocon E, Becker G and Loning T (1998) p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79:61-65
23. Niederacher D, Picard F, van Roeyen C, An HX, Bender HG and Beckmann MW (1997) Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. Genes Chromosomes Cancer 18: 181-192
24. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond) 368: 753-756
25. Schultz DC, Vanderveer I., Buelow KH, Boente MP, Ozols RF, Hamilton TC and Godwin AK (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55: 2150-2157
26. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
27. Shigemasa K, Hu C, West CM, Clark J, Parham GP, Parmley TH, Korourian S, Baker VV and O'Brien TJ (1997) p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 4: 95-102
28. Shih YC, Kerr J, Liu J, Hurst T, Khoo SK, Ward B, Wainwright B and Chenvevix-Trench G (1997) Rare mutations and to hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer 70: 508-511
29. Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC and Jones PA (1994) p16 gene uncultured tumours. Nature (Lond) 370: 183-184